East
Rutherford, NJ - December 11, 2009 -- Renowned mycologist Prof. Hirokazu Kawagishi, PhD, presented"amyloban, The
Mane for Your Brain," a major address on the anti-dementia potential of extracts from Lion's
Mane (Hericium erinaceum) mushrooms, at the 17th Annual World
Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies
(A4M), to be held from December 9th – 12th, 2009 at the
Mandalay Bay Hotel & Convention Center, Las Vegas, Nevada.
Professor
Kawagishi's presentation took
place on Friday, December 11th, at 7am, and despite the Early Bird time slot, over 150 practitioners were
in attendance.
A4M is a preeminent global integrative medicine and anti-aging conference
attended by over 4,000 doctors, researchers and practitioners.
Amyloban is a
patented Lion's Mane active fraction discovered by a research team led by
Professor Kawagishi, Shizuoka
University, Japan
and Cun Zhuang, PhD., Vice-President of Research & Development for Mushroom
Wisdom, Inc. (formerly Maitake Products, Inc.), East Rutherford, New
Jersey. (Japanese patent 394,3399). Results
from studies conducted by Professor Kawagishi
indicate that Amyloban inhibits the toxicity of plaques containing
amyloid beta peptide (AβP). Since it is known that AβP
causes neuron destruction characteristic of Alzheimer's disease, Professor
Kawagishi believes that amyloban has the potential to exert a protective
effect on brain cells.*
In
earlier research, Professor Kawagishi
discovered a new class of Lion's Mane compounds called hericenones, the first natural, non animal-based substances found to stimulate
production of Nerve Growth Factor (NGF) in the brain. Both amyloban and hericenones are contained in Amyloban®
3399, a breakthrough brain support supplement available from Mushroom Wisdom.*
"Brain
cell protection and regeneration are essential for mental clarity as we age,"
said Michael Shirota, Mushroom Wisdom President & CEO. "We believe that Professor Kawagishi's
research and our resultant development of Amyloban® 3399 are important steps in
the war on Alzheimer's and other neurological diseases."
Professor
Kawagishi's study is part of extensive mycological research supported by
Mushroom Wisdom, Inc. The company has sponsored important studies
on the health and wellness impact of medicinal mushrooms in association with
teams from leading universities and medical centers including Shizuoka University,
Memorial Sloan Kettering Cancer Center, New York Medical College and Georgetown University. The company's Maitake D-Fraction®
tincture has received IND (Investigational New Drug) approval from
the FDA for Phase II clinical studies on advanced breast and prostate cancer
patients.
Mushroom
Wisdom, Inc. (formerly Maitake Products, inc.) is a global leader in the
development, production and research of medicinal mushroom extract
supplements. The company brings the
healthful benefits of medicinal mushrooms, backed by scientific research, to the
daily routines of consumers worldwide.
It offers a complete supplement product line, including specific
medicinal mushroom extracts developed to support the immune system, brain
function, blood sugar levels, breast health, prostate health and more.*
* These
statements have not been evaluated by the Food and Drug Administration. These products are not intended to
diagnose, treat, cure or prevent any disease.
